Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
33.21
+0.07 (0.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for APLS stock have an average target of 49.89, with a low estimate of 24 and a high estimate of 106. The average target predicts an increase of 50.23% from the current stock price of 33.21.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for APLS stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 8 | 8 | 7 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 5 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 17 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $36 | Strong Buy → Hold | Downgrades | $36 | +8.40% | Dec 17, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $31 | Hold | Initiates | $31 | -6.65% | Nov 21, 2024 |
| Baird | Baird | Buy Maintains $92 → $55 | Buy | Maintains | $92 → $55 | +65.61% | Nov 7, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $63 → $51 | Strong Buy | Maintains | $63 → $51 | +53.57% | Nov 6, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $71 → $36 | Strong Buy | Maintains | $71 → $36 | +8.40% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
775.47M
from 396.59M
Increased by 95.53%
Revenue Next Year
875.78M
from 775.47M
Increased by 12.94%
EPS This Year
-1.73
from -4.45
EPS Next Year
-0.96
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 813.2M | 1.1B | 2.2B | |||
| Avg | 775.5M | 875.8M | 1.1B | |||
| Low | 725.0M | 757.9M | 872.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 105.1% | 36.2% | 147.1% | |||
| Avg | 95.5% | 12.9% | 29.6% | |||
| Low | 82.8% | -2.3% | -0.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.65 | 0.08 | 7.06 | |||
| Avg | -1.73 | -0.96 | 1.18 | |||
| Low | -1.96 | -1.70 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.